Renaissance Capital logo

Genfit Priced, Nasdaq: GNFT

Phase 3 French biotech developing therapies for NASH.

Industry: Health Care

Latest Trade: $15.01 0.00 (0.0%)

First Day Return: +9.1%

Return from IPO: -26.1%

Industry: Health Care

We are a late-stage clinical biopharmaceutical company dedicated to the discovery and development of innovative drug candidates and diagnostic solutions targeting metabolic and liver-related diseases where there is considerable unmet medical need. We are a leader in the field of nuclear receptor-based drug discovery with a rich history and strong scientific heritage spanning almost two decades. We are evaluating our most advanced drug candidate, elafibranor, in a pivotal Phase 3 clinical trial as a potential treatment for nonalcoholic steatohepatitis, or NASH, and as a potential treatment for primary biliary cholangitis, or PBC. In December 2018, we announced positive preliminary results from our Phase 2 clinical trial in PBC. Our drug discovery efforts are based on selecting appropriate nuclear receptors as targets and utilizing rational drug design to optimize our drug candidates. A key differentiator of our development strategy is our NASH biomarker-based diagnostic program, in which we are developing a new in vitro diagnostic, or IVD, test to identify patients with NASH who may be appropriate candidates for drug therapy. Our scientific and clinical expertise, translational disease-driven approach and strong bioinformatics capabilities have allowed us to build a scientific platform through which we discover and develop our drug candidates and diagnostic tools. We believe elafibranor, if approved, has the potential to become a first-line treatment as a monotherapy and the backbone of combination regimens.
more less
IPO News for Genfit
more
IPO Data
IPO File Date 02/27/2019
Offer Price $20.32
Price Range $20.32 - $20.32
Offer Shares (mm) 6.7
Deal Size ($mm) $135
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 03/26/2019
Offer Price $20.32
Price Range $20.32 - $20.32
Offer Shares (mm) 6.7
Deal Size ($mm) $135
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Loos, France
Founded 1999
Employees 150
Website www.genfit.com